Evaluation on the therapeutic efficacy of the combined immunosuppression therapy in children with aplastic anemia
Chen Jing,Pan Ci,Dong Lu,Ye Hui,Zhou Min,Tang Jingyan,Xue Huiliang,Gu Longjun,Wang Yaoping
DOI: https://doi.org/10.3969/j.issn.1673-5323.2006.04.003
2006-01-01
Abstract:Objective Beginning from Aug. 1996~Setp.2004. 85 children with aplastic anemia aged from 1~14 years were enrolled in hematology dept. 72 patients were followed up until Mar. 2005. To analyse 72 children with aplastic anemia, the therapeutic efficacy of the combined immunosuppression therapy and the prognosis of these patients was evaluated.Methods In total of 72 children with aplastic anemia, 30 cases with chronic aplastic anemia received androgen, CSA, while 42 cases with acute aplastic anemia received androgen, CSA, high-dose IGIV, ATG. 2 cases with acute aplastic anemia received Allo-genic peripheral blood stem cell transplantion(Allo-PBSCT). The clinical characteristics, therapeutic effect, relapse rate, mortality, the incidence of second malignant diseases and survival rate were analysed. The standard for diagnosis and therapentic effect evaluation was based on the criteria the 4 th Chinese national conference on aplastic anemia. Results There was no statistical difference in sex and age distribution between the children with chronic aplastic anemia or acute aplastic anemia. (P>0.05). 17 cases of 30 cases with chronic group had got improvement or cure, 11 cases with chronic type failed, with no case died. 14 cases from acute group had achieved improvement or cure, 20 cases failed, 7 cases died, with no case relapsed in both groups. The effective rate in chronic group was higher than that in acute group(56.67% vs 33.33%, P<0.05). The overall survival rate was different between these two groups (100% vs 83.33% P>0.05). The time of effect occurred was of no marked difference between these two groups (P>0.05). While the average interval of transfusion was of significant difference between these two groups (P<0.005). 28 cases of 42 cases with acute group received ATG, with 11 cases achieved improvement or cure, while only 3 cases without ATG treatment had effect with statistical difference between ATG group and no ATG group (42.13% vs 21.43%, P<0.05). 3 of 72 patients with aplastic anemia developed AML (M_1, M_3, M_5 respectively), then they received chemotherapy, while 2 patients were cured after receivine Allo-PBSCT.Conclusion The therapeutic effect and survival rate in children with chronic aplastic anemia was significantly higher than that of children with acute aplastic anemia, indicating the combined immunosuppressive therapy was the most effective therapy in addition to the Allo-PBSCT in the treatment of children with acute aplastic anemia.